Enovis Corporation (ENOV)
| Market Cap | 1.35B |
| Revenue (ttm) | 2.25B |
| Net Income (ttm) | -1.18B |
| Shares Out | 57.54M |
| EPS (ttm) | -20.75 |
| PE Ratio | n/a |
| Forward PE | 6.49 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 746,174 |
| Open | 24.53 |
| Previous Close | 24.54 |
| Day's Range | 22.94 - 24.72 |
| 52-Week Range | 21.00 - 37.85 |
| Beta | 1.59 |
| Analysts | Strong Buy |
| Price Target | 47.38 (+102.48%) |
| Earnings Date | May 7, 2026 |
About ENOV
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary ca... [Read more]
Financial Performance
In 2025, Enovis's revenue was $2.25 billion, an increase of 6.66% compared to the previous year's $2.11 billion. Losses were -$1.18 billion, 43.5% more than in 2024.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for ENOV stock is "Strong Buy." The 12-month stock price target is $47.38, which is an increase of 102.48% from the latest price.
News
Analyst Backs Enovis On Cash Flow Turnaround
The firm argued that while the stock has lagged over the past two years, execution on cash flow could unlock multiple expansion opportunities.
Enovis to Host First Quarter 2026 Results Conference Call on May 7th
Dallas, TX, April 10, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and li...
Enovis Transcript: 2026 CG Musculoskeletal Conference
Solid 2025 growth was driven by double-digit gains in extremities and international recon, increased R&D investment, and successful integration of acquisitions. New technology launches, especially in ARVIS and hip products, are set to drive further growth in 2026, with strong momentum in ASCs and international markets.
Enovis Earnings Call Transcript: Q4 2025
Delivered strong 2025 results with 7% sales growth, margin expansion, and positive free cash flow. 2026 guidance calls for 4–6% organic growth, higher margins, and a step-up in free cash flow conversion, supported by robust innovation and disciplined capital allocation.
Update: Enovis Announces Fourth Quarter and Full Year 2025 Results
Dallas, TX, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and...
Enovis Announces Fourth Quarter and Full Year 2025 Results
Dallas, TX, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and...
Enovis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Dallas TX, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that management will participate in the BTIG 13t...
Enovis to Host Fourth Quarter and Full Year 2025 Results Conference Call on February 26th
Dallas, TX, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and liv...
Top 3 Health Care Stocks That Could Blast Off This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Enovis Transcript: 44th Annual J.P. Morgan Healthcare Conference
Revenue and margin growth are driven by a balanced global portfolio, innovation, and operational improvements. New product launches and integration of recent acquisitions support a positive outlook, with a focus on commercial execution and free cash flow generation.
Enovis to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Dallas, TX, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will meet with investo...
Enovis Appoints Oliver Engert as Chief Administrative Officer
Dallas, TX, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology company, has announced that Oliver Engert has been appointed Chief Administrativ...
Enovis Transcript: Jefferies London Healthcare Conference 2025
Management highlighted strong product innovation, successful integration of acquisitions, and a balanced portfolio driving above-market growth. Focus remains on operational excellence, cash flow, and leveraging new technologies, with updated strategic guidance expected in January.
Enovis Transcript: UBS Global Healthcare Conference 2025
Maintains a balanced, innovative orthopedic portfolio with strong U.S. and international presence, focusing on commercial execution, operational excellence, and cash flow. Key growth drivers include new product launches, especially in shoulder and navigation tech, and ongoing integration of recent acquisitions.
Enovis Earnings Call Transcript: Q3 2025
Third quarter revenue grew 9% year-over-year, with strong organic growth in both Recon and P&R segments. Adjusted gross margins and EPS improved, while guidance for full-year revenue and profit was raised. The Dr. Comfort divestiture and new product launches support a focus on higher-growth, higher-margin opportunities.
Enovis Announces Third Quarter 2025 Results
Dallas, TX, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial result...
Enovis announces webcast and conference call for Third Quarter 2025 Results and participation in upcoming investor conferences
Dallas, TX, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, announced today it will host an inve...
Enovis completes sale of its Dr. Comfort Footcare Solutions business for proceeds of up to $60 million
Wilmington, DE, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced the sale of its ...
Enovis Transcript: Baird Global Healthcare Conference 2025
Management outlined a shift to organic growth and operational excellence, with strong hip and knee demand, a focus on innovation, and improved financial discipline. ARVIS 2.0 and new product launches are expected to drive future growth, while tariff and integration headwinds are easing.
Enovis Corporation Announces Time Change for Presentation at Baird 2025 Global Healthcare Conference
Wilmington, DE, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that it will now present at the Baird 2025...
Enovis Transcript: Wells Fargo 20th Annual Healthcare Conference 2025
Management outlined a strategy focused on organic growth, operational excellence, and debt reduction, with new product launches and flexible ARVIS models driving future momentum. Margin expansion, cash flow improvement, and tariff mitigation are key priorities, while macroeconomic and regulatory risks remain watchpoints.
Enovis to Participate in Upcoming Investor Conferences
Wilmington, DE, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate i...
Enovis Earnings Call Transcript: Q2 2025
Q2 sales rose 7% to $565M, with recon up 8% and P&R up 3%. Guidance for revenue, organic growth, and margins was raised, reflecting strong product launches and improved currency. Capital allocation is focused on debt reduction, with positive free cash flow expected for 2025.
Enovis Announces Second Quarter 2025 Results
Wilmington, DE, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial re...
Enovis to Host Second Quarter 2025 Results Conference Call on August 7th
Wilmington, DE, July 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and...